Skip to main content
Premium Trial:

Request an Annual Quote

UK Funds Challenge Trial

The UK is investing millions of pounds into a human SARS-CoV-2 challenge study in which healthy volunteers will be given the virus in the hopes of better understanding infections and accelerating vaccine development, according to Reuters.

It adds that the UK is investing £33.6 million (US $43.5 million) in the study, which is to be run jointly by Imperial College London, the Royal Free London NHS Foundation Trust, and the lab and clinical trial services company hVivo. The trial aims to initially enroll up to 90 healthy volunteers between the ages of 18 and 30 to receive controlled doses of the virus to gauge the minimum amount of virus to which someone has to be exposed to cause COVID-19. 

Critics of human challenge studies argue that deliberately exposing people to a potentially deadly disease with no cure is unethical, Reuters adds.

"Deliberately infecting volunteers with a known human pathogen is never undertaken lightly," study co-investigator Peter Openshaw tells the Associated Press. "However, such studies are enormously informative about a disease, even one so well studied as COVID-19."

The Scan

Foxtail Millet Pangenome, Graph-Based Reference Genome

Researchers in Nature Genetics described their generation of a foxtail millet pangenome, which they say can help in crop trait improvement.

Protein Length Distribution Consistent Across Species

An analysis in Genome Biology compares the lengths of proteins across more than 2,300 species, finding similar length distributions.

Novel Genetic Loci Linked to Insulin Resistance in New Study

A team reports in Nature Genetics that it used glucose challenge test data to home in on candidate genes involved in GLUT4 expression or trafficking.

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.